References
- Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S, Dent P. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biol Ther 2013; 14:458 - 65; http://dx.doi.org/10.4161/cbt.24424; PMID: 23917378
- Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39:8 - 24; http://dx.doi.org/10.1016/j.molcel.2010.06.017; PMID: 20603072
- Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123 - 34; http://dx.doi.org/10.1056/NEJMoa0900212; PMID: 19553641
- Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12:852 - 61; http://dx.doi.org/10.1016/S1470-2045(11)70214-5; PMID: 21862407
- Pierce A, McGowan PM, Cotter M, Mullooly M, O’Donovan N, Rani S, O’Driscoll L, Crown J, Duffy MJ. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther 2013; 14:537 - 45; http://dx.doi.org/10.4161/cbt.24349; PMID: 23760496